spacer
home > ebr > autumn 2018 > determining peptides
PUBLICATIONS
European Biopharmaceutical Review

Determining Peptides

Therapeutic peptides are often applied via the following routes: intramuscular (IM), intraperitoneal (IP), intravenous (IV), or inhalative. Only a few peptides are stable in the stomach (acidic plus pepsin digestion) and the intestine (trypsin digestion) after oral application. Determination in plasma is very complex, as far as selectivity is concerned, because millions of endogenous peptides and proteins can be found in plasma.

Usually, the determination of a drug in plasma starts with some questions:

• How much of that drug is applied per kg body weight
• Which route of application is used (IM, IP, IV, oral, or inhalative)
• Is anything known about the first pass effect (leading to metabolites and, therefore, lowering the parent drug concentration)
• Does the molecule show a high volume of bodily distribution (which often means that the molecule shows very lipophilic characteristics or high tissue attraction and, therefore, a fast elimination half-life and low concentration levels in plasma

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Hermann Mascher, bioanalytical consultant and founder of pharm-analyt Labor, has more than 100 publications in peer reviewed journals (with more than a 230 impact factor). Hermann is the inventor of three patents for biomarkers in the area of rare lysosomal storage diseases and has developed analytical methods for dozens of peptides.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement